Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer


Debt - II | Alive

Total Raised


Last Raised

$2M | 9 yrs ago

About Sonexa Therapeutics

Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease. ST101, the company's lead compound, represents an agent that, in animal models, has demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. ST101 has completed Phase I studies in both healthy volunteers and AD patients. It is being evaluated in Phase II Proof-of-Concept trials.

Sonexa Therapeutics Headquarter Location

12555 High Bluff Drive

San Diego, California, 92101,

United States

Latest Sonexa Therapeutics News

Raising Funds: AnaptysBio, Sonexa, Eclipse, NextDx, Naviscan

Oct 18, 2011

XconomySan Diego —  There’s been a flurry of funding deals among San Diego life sciences companies in recent weeks, led by AnaptysBio, a six-year-old startup that named a new executive chairman and chief business officer just last week. Here’s a rundown of recent activity: —AnaptysBio, founded in 2005 with technology to discover and optimize potent antibodies to fight disease, has raised $8 million of a targeted $22 million financing, according to a recent filing with the Securities and Exchange Commission. The financing includes equity, warrants, and securities. The company raised almost $34 million four years ago in a Series B round led by Novo A/S, a Novo Group holding company wholly owned by the Novo Nordisk Foundation. San Diego’s Avalon Ventures also was an investor, and Avalon founder Kevin Kinsella remains on the startup’s board. Other investors include Frazier Healthcare Investors, Numenor Ventures, Alloy Ventures, and WS Investment Co. —Sonexa Therapeutics, a privately-held biotech developing new drug treatments for Alzheimer’s disease and related disorders, has raised $1 million of a planned $2.5 million in warrants and securities, according to a recently regulatory filing . Domain Associates led a $30 million Series A funding round in 2008, and Domain partner Eckard Weber is identified as CEO in the filing. Other investors include Alta Partners, Scale Venture Partners, AgeChem Venture Fund, and MC Life Science Ventures. —Eclipse Therapeutics, a biotech developing drugs that target cancer stem cells, has raised nearly $2.8 million of a planned $3 million in debt, warrants, and securities, according to a recent regulatory filing . In March, the company announced the close of $2 million in seed funding led by its founding investor, City Hill Ventures, and the filing indicates that the new funding is an extension of that deal. City Hill Ventures’ founding partner, Jonathan Lim, was named as the executive chairman in March. He was previously the CEO of San Diego-based Halozyme Therapeutics. Another recent filing shows Lim as the founder and funder of another San Diego startup, NextDx, which recently raised $250,000 of a planned $500,000 in  funding. —Naviscan, a San Diego startup developing organ-specific imaging technology that uses Positron Emission Tomography (PET) scanners, has expanded funding of a planned $363,000 round disclosed last month . Since then, Naviscan has raised a total of $830,000 of a planned $2.2 million financing that includes debt, warrants, and securities, according to a regulatory filing .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sonexa Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sonexa Therapeutics is included in 3 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.



2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.



5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Sonexa Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sonexa Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.